The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.
Reinhard Dummer
Consultant or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; Genta; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche; Spirig Pharma AG; Transgene
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; Genta; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche; Spirig Pharma AG; Transgene
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche; Transgene
Caroline Robert
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Marta Nyakas
No relevant relationships to disclose
Grant A. McArthur
Consultant or Advisory Role - Millennium (U); Novartis (U); Pfizer (U); Roche/Genentech (U)
Research Funding - Millennium; Novartis; Pfizer
Ragini Reiney Kudchadkar
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Carlos Gomez-Roca
No relevant relationships to disclose
Ryan J. Sullivan
No relevant relationships to disclose
Keith Flaherty
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Carla Murer
No relevant relationships to disclose
Daniela Michel
Employment or Leadership Position - Novartis
Zhongwen Tang
Employment or Leadership Position - Novartis
Laure A. De Parseval
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jean-Pierre Delord
No relevant relationships to disclose